



EXPRESS MAIL MAILING LABEL  
NO.: EV68999516545

PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			<b>Complete if Known</b>	
			Application Number	10/773,032
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Filing Date	February 5, 2004
			First Named Inventor	Lee
			Art Unit	1631
			Examiner Name	Lin, Jerry
(Use as many sheets as necessary)			Attorney Docket Number	EPT-001C2
Sheet	1	of	3	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
JL	A18	4,478,744	10/23/1984	Mezel <i>et al.</i>	
	A19	6,113,897	9/5/2000	Oano <i>et al.</i>	
	A20	6,225,047	5/1/2001	Hutchens	
	A21	2004/0229284	11/18/2004	Luciw <i>et al.</i>	
	A22	2005/0214304	9/28/2005	Pastan <i>et al.</i>	
	A23	2005/0153298	7/14/2005	Gembitsky <i>et al.</i>	
	A24	2003/0054408 A1	3/20/2003	Ravi <i>et al.</i>	
	A25	5,708,155	1/13/1998	Potter <i>et al.</i>	
	A26	5,763,158	6/9/1998	Bohannon <i>et al.</i>	
	A27	5,790,155	8/4/1998	Usui <i>et al.</i>	
	A28	5,798,155	8/25/1998	Yanagawa <i>et al.</i>	
	A29	5,872,234	2/16/1999	Bandman <i>et al.</i>	
	A30	5,961,923	10/5/1999	Nova <i>et al.</i>	
	A31	6,261,569	7/17/2001	Comis <i>et al.</i>	
	A32	6,420,125	7/16/2002	Fiedelius <i>et al.</i>	
	A33	2002/0042386 A1	4/11/2002	Rosen <i>et al.</i>	
	A34	2002/0055186 A1	5/9/2002	Bamy <i>et al.</i>	
	A35	2002/0081617 A1	6/27/2002	Buranda <i>et al.</i>	
	A36	2003/0028330 A1	2/6/2003	Cheng <i>et al.</i>	
	A37	2003/0032039 A1	9/12/2002	Cunningham <i>et al.</i>	
	A38	2003/0044862 A1	3/6/2003	Giaccla <i>et al.</i>	
	A39	2004/0038307 A1	2/26/2004	Lee <i>et al.</i>	
	A40	2004/0180380 A1	9/16/2004	Lee <i>et al.</i>	
	A41	2006/0014212	1/19/2006	Benkovic <i>et al.</i>	
	A42	2006/0035270 A1	2/16/2006	Lee <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
JL	B4	DE 40 23 945	1/30/1992		Abstract only in English	
	B5	EP 0 337 057	1/23/1989		Abstract only in English	
	B6	EP 0 267 355	3/27/1987		Abstract only in English	
	B7	WO 05/50223	6/2/2005			
	B8	WO 05/78453	8/25/2005			
	B9	JP 07285999 A	10/31/1995			
	B10	WO 02/06834 A	1/24/2002			
	B11	WO 99/39210 A	8/5/1999			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Examiner Signature	/Jerry Lin/	Date Considered	01/11/2007
-----------------------	-------------	--------------------	------------

Substitute for form 1449A/B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/773,032	
			Filing Date	February 5, 2004	
			First Named Inventor	Lee	
			Art Unit	1631	
			Examiner Name	Lin, Jerry	
Sheet	2	of	3	Attorney Docket Number	EPT-001C2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
JL	C14	Amheiter <i>et al.</i> (1981) "Physicochemical and Antigenic Properties of Synthetic Fragments of Human Leukocyte Interferon," <i>Nature</i> 294: 278-80.		
	C15	Amon (1991) "Synthetic Peptides as the Basis for Vaccine Design," <i>Molecular Immunology</i> 28(3): 209-215.		
	C16	Barbas III <i>et al.</i> (1991) "Assembly of Combinatorial Antibody Libraries on Phage Surfaces: The Gene III Site," <i>PNAS USA</i> 88: 7978-7982.		
	C17	Barry <i>et al.</i> (2003) "Competitive Assay Formats for High-Throughput Affinity Arrays," <i>J. Biomol. Screen.</i> 10(3): 257-263.		
	C18	Borreback (2000) "Antibodies in Diagnostics - From Immunoassays to Protein Chips," <i>Immunology Today</i> 21(8): 379-381.		
	C19	Chames <i>et al.</i> (2000) "Antibody Engineering and its Applications in Tumor Targeting in Intracellular Immunization," <i>FEMS Microbiology Letters</i> 189: 1-8.		
	C20	Chou <i>et al.</i> (1974) "Prediction of Protein Conformation," <i>Biochemistry</i> 13(2): 222-245.		
	C21	Devereux <i>et al.</i> (1984) "A Comprehensive Set of Sequence Analysis Programs for the VAX," <i>Nucleic Acids Research</i> 12 (1): 387-395.		
	C22	Erall <i>et al.</i> (1996) "ELISA for Thyroglobulin in Serum: Recovery Studies to Evaluate Autoantibody Interference and Reliability of Thyroglobulin Values," <i>Clinical Chemistry</i> 42: 766-770.		
	C23	European Supplementary Search Report for EPSN 03808371, completed 06/01/2006, dated 06/12/2006.		
	C24	Harper <i>et al.</i> (1998) Two-Dimensional Gel Electrophoresis, Unit 10.4, <i>Current Protocols in Protein Science</i> , pgs. 10.4.1 to 10.4.36.		
	C25	Haupt <i>et al.</i> (1998) "Plastic Antibodies: Developments and Applications," <i>Trends Biotech.</i> 16: 468-476.		
	C26	Hellmold <i>et al.</i> (2002) "Identification of End Points Relevant to Detection of Potentially Adverse Drug Reactions," <i>Toxicology Letters</i> 127: 239-243.		
	C27	Hemminki <i>et al.</i> (1998) "Fine Tuning of an Anti-Testosterone Antibody Binding Site by Stepwise Optimisation of the CDRs," <i>Immunotechnology</i> 4: 59-69.		
	C28	Hennig (1998) "WinPep-ein Programm zur Analyse von Aminosäuresequenzen," <i>Biospektrum</i> 4(5): 49-50.		
	C29	Hoogenboom <i>et al.</i> (1998) "Antibody Phage Display Technology and its Applications," <i>Molecular Immunology</i> 4: 1-20.		
	C30	Hoogenboom <i>et al.</i> (2000) "Natural and Designer Binding Sites Made by Phage Display Technology," <i>Immunology Today</i> 21(8): 371-378.		
	C31	Hopp <i>et al.</i> (1983) "A Computer Program For Predicting Protein Antigenic Determinants," <i>Molecular Immunology</i> 20(4): 483-489.		
	C32	International Search Report for PCT/US2003/014846, mailed on 11/20/2004.		
	C33	International Search Report for PCT/US2004/038282, mailed on 12/22/2006.		
	C34	International Search Report for PCT/US2005/003634, mailed on 09/15/2006.		
JL	C35	Kuruvilla <i>et al.</i> (2002) "Dissecting Glucose Signaling with Diversity-Oriented Synthesis and Small-Molecule Microarrays," <i>Nature</i> 416: 653-657.		
	C36	Kyte <i>et al.</i> (1982) "A Simple Method for Displaying the Hydropathic Character of a Protein," <i>J. Mol. Biol.</i> 157: 105-132.		
	C37	Lesko <i>et al.</i> (2001) "Use of Biomarkers and Surrogate Endpoints in Drug Development and Regulatory Decision Making: Criteria, Validation, Strategies," <i>Annu. Rev. Pharmacol. Toxicol.</i> 41: 347-366.		
	C38	Li (2000) "Application of Display Technology in Protein Analysis," <i>Nature Biotechnology</i> 18: 1251-1256.		
	C39	Lizardi <i>et al.</i> (1998) "Mutation Detection and Single Molecule Counting Using Isothermal Rolling Circle Amplification," <i>Mat. Genet.</i> 19: 225-232.		
	C40	Maggio (1980) <i>Enzyme-immunoassay</i> , pgs. 53-70.		
	C41	Mariani <i>et al.</i> (1987) "Immunogenicity of a Free Synthetic Peptide: Carrier Conjugation Enhances Antibody Affinity for the Native Protein," <i>Molecular Immunology</i> 24(3): 297-303.		
	C42	Marks <i>et al.</i> (1992) "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," <i>Bio/Technology</i> 10: 779-783.		
Examiner Signature	/Jerry Lin/		Date Considered	01/11/2007

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/773,032
				Filing Date	February 5, 2004
				First Named Inventor	Lee
				Art Unit	1631
				Examiner Name	Lin, Jerry
Sheet	3	of	3	Attorney Docket Number	EPT-001C2

JL	C43	Michaud <i>et al.</i> (2003) "Analyzing Antibody Specificity with Whole Proteome Microarrays," Nat. Biotech. 21(12) 1509-12 (e-publication 11/9/03).	
	C44	Nelson <i>et al.</i> (2000) "Demystified... Monoclonal Antibodies," J. Clin. Pathol.: Mol. Pathol. 53: 111-117.	
	C45	Ohlin <i>et al.</i> (1996) "Light Chain Shuffling of a High Affinity Antibody Results in a Drift in Epitope Recognition," Molecular Immunology 33(1): 47-56.	
	C46	Rosenkranz (2003) "Biomarkers and Surrogate Endpoints in Clinical Drug Development," Applied Clinical Trials, pgs. 30-34, 40.	
	C47	Schweitzer <i>et al.</i> (2002) "Multiplexed Protein Profiling on Microarrays by Rolling-Circle Amplification," Nat. Biotechnol. 20: 359-365.	
	C48	Scrivener <i>et al.</i> (2003) "Peptidomics: A New Approach to Affinity Protein Microarrays," Proteomics 3: 112-128.	
	C49	Shea <i>et al.</i> (1993) "Immunologic Detection and Measurement of Glycated Apolipoprotein B with Site Specific Monoclonal Antibodies," J. Immunol. Methods 162(1): 85-95.	
	C50	Soderlind <i>et al.</i> (1999) "Complementary-Determining Region (CDR) Implantation: A Theme of Recombination," Immunotechnology 4: 279-285.	
	C51	Soderlind <i>et al.</i> (2000) "Recombining Germline-Derived CDR Sequences for Creating Diverse Single-Framework Antibody Libraries," Nature Biotechnology 18: 852-856.	
	C52	Soloveiv <i>et al.</i> (2003) "Combinatorial Peptidomics: A Generic Approach for Protein Expression Profiling," J. of Nanobiotechnology 1: 4-19.	
	C53	Viatakis <i>et al.</i> (1993) "Drug Assay Using Antibody Mimics Made by Molecular Imprinting," Nature 361: 645-647.	
	C54	Weckwerth (2003) "Metabolomics in Systems Biology," Annu. Rev. Plant Biol. 54: 669-689.	
	C55	Werkmeister <i>et al.</i> (1991) "Multiple Antigenic Determinants on Type III Collagen," Biochem. J. 274: 895-898.	
	C56	Whaley <i>et al.</i> (1991) "Identification of Nearest-Neighbor Peptides in Protease Digests by Mass Spectrometry for Construction of Sequence-Ordered Tryptic Maps," Biological Mass Spectrometry 20: 210-14.	

LIBC/2847873.1

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Jerry Lin/	Date Considered	01/11/2007
--------------------	-------------	-----------------	------------